By Deanna DePeau
The FDA approved the use of a risperidone-containing long-acting injectable (Perseris, Indivior), designed for the treatment of schizophrenia in adults.
Risperidone uses an extended-release delivery system that forms a subcutaneous depot to provide continual levels of the drug over a one-month period.
“Treatment adherence is a major challenge in schizophrenia due to the complexity of the disease. It is important to have additional treatment options available to physicians to